Skip to main content

Rosetta to Expand Sales Territories, Rebrands Lead Cancer Diagnostic

Premium

Rosetta Genomics this week announced that it plans to expand its US commercial operations from five sales territories to 12 next month.

The company also said that it has rebranded its flagship microRNA-based diagnostic MiRview Mets2, which is designed to identify the source of cancers of unknown primary origin, as the Rosetta Cancer Origin test.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.